NASDAQ:GRFS - GRIFOLS S A/S Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$18.51
▲ +0.31 (1.70%)
1 month | 3 months | 12 months
Get New GRIFOLS S A/S Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GRFS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GRFS

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 10 analysts offering 12 month price targets for GRIFOLS S A/S in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $18.51.
Buy
The current consensus among 10 polled investment analysts is to buy stock in GRIFOLS S A/S.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings
5/2/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
7/31/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 0 sell ratings
9/23/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 0 sell ratings
10/23/2020

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/1/2020CitigroupUpgradeSell ➝ NeutralLow
i
9/30/2020Morgan StanleyReiterated RatingOverweightLow
i
7/21/2020Berenberg BankReiterated RatingBuyLow
i
6/23/2020Morgan StanleyReiterated RatingOverweightLow
i
6/10/2020Berenberg BankReiterated RatingBuyMedium
i
6/9/2020CitigroupDowngradeNeutral ➝ SellMedium
i
6/9/2020HSBCUpgradeReduce ➝ HoldMedium
i
6/1/2020BarclaysReiterated RatingOverweightLow
i
4/21/2020JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralMedium
i
3/27/2020Kepler Capital MarketsReiterated RatingHoldMedium
i
3/25/2020CitigroupDowngradeBuy ➝ NeutralLow
i
3/6/2020JPMorgan Chase & Co.Reiterated RatingOverweightLow
i
3/1/2020Kepler Capital MarketsReiterated RatingHoldHigh
i
12/12/2019William BlairReiterated RatingOutperformLow
i
Rating by M. Kaczor at William Blair
12/9/2019Banco SabadellUpgradeSell ➝ BuyMedium
i
10/30/2019Berenberg BankUpgradeBuyLow
i
10/28/2019SantanderUpgradeHold ➝ BuyLow
i
6/27/2019JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$21.00 ➝ $22.50High
i
2/8/2019Berenberg BankDowngradeBuy ➝ HoldHigh
i
Rating by Tom Jones at Berenberg Bank
1/2/2019Morgan StanleyLower Price TargetUnderweight ➝ Underweight$20.00 ➝ $19.00Low
i
10/30/2018SantanderUpgradeUnderperform ➝ HoldLow
i
10/11/2018Berenberg BankUpgradeHold ➝ BuyMedium
i
10/3/2018UBS GroupDowngradeNeutral ➝ SellHigh
i
10/1/2018Morgan StanleyLower Price TargetUnderweight ➝ Underweight$22.00 ➝ $20.00Low
i
6/13/2018JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralLow
i
6/1/2018BarclaysInitiated CoverageOverweightMedium
i
3/14/2018HSBCUpgradeReduce ➝ HoldLow
i
3/1/2018Morgan StanleyLower Price TargetUnderweight ➝ Underweight$23.00 ➝ $22.00Medium
i
11/24/2017UBS GroupDowngradeOutperform ➝ Market PerformN/A
i
10/31/2017CitigroupInitiated CoverageBuy ➝ BuyN/A
i
7/4/2017Bank of AmericaReiterated RatingBuyMedium
i
6/30/2017Goldman Sachs GroupDowngradeBuy ➝ NeutralLow
i
4/6/2017Bank of AmericaInitiated CoverageBuy ➝ BuyLow
i
3/30/2017JPMorgan Chase & Co.UpgradeNeutral ➝ OverweightHigh
i
2/27/2017Goldman Sachs GroupDowngradeConviction-Buy ➝ BuyN/A
i
1/3/2017JPMorgan Chase & Co.UpgradeNeutral ➝ OverweightN/A
i
12/13/2016UBS GroupDowngradeBuy ➝ NeutralN/A
i
6/6/2016Morgan StanleyReiterated RatingSellN/A
i
Rating by James Francescone at Morgan Stanley
5/23/2016UBS GroupUpgradeSell ➝ BuyN/A
i
5/8/2016Morgan StanleyReiterated RatingSellN/A
i
Rating by James Francescone at Morgan Stanley
3/17/2016Nomura SecuritiesInitiated CoverageBuyN/A
i
2/9/2016Berenberg BankUpgradeHold ➝ BuyN/A
i
1/4/2016Morgan StanleyDowngradeEqual Weight ➝ UnderweightN/A
i
11/20/2015Berenberg BankDowngradeBuy ➝ HoldN/A
i
(Data available from 10/24/2015 forward)
GRIFOLS S A/S logo
Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products. It offers plasma products, such as intravenous immune globulin, Factor VIII, alpha-1 proteinase inhibitor, and albumin; and intramuscular immunoglobulins, antithrombin III, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products, including analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. It serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment offers products used by hospitals, as well as parenteral solutions and enteral nutritional fluids. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides infusion solutions, nutrition products, and medical devices for use in hospitals and clinics; and engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. The company was founded in 1940 and is headquartered in Barcelona, Spain.
Read More

Today's Range

Now: $18.51
$18.22
$18.56

50 Day Range

MA: $17.13
$15.40
$19.63

52 Week Range

Now: $18.51
$13.40
$25.73

Volume

1,287,535 shs

Average Volume

1,254,528 shs

Market Capitalization

$12.73 billion

P/E Ratio

20.57

Dividend Yield

0.93%

Beta

0.65